6Riordan H J, Antonini P, Murphy M F. Atypical antipsy- chotics and metabolic syndrome in patients with schizo- phrenia : risk factors, monitoring and heahhcare implica- tions[ J]. Am Health Drug Benefits,2011,4 (5) :292 - 302.
7Buckley P F, Foster A. Schizophrenia:current concepts and approaches to patient care [ J ]. Am Health Drug Benefits, 2008,1 (d) : 13 - 22.
8Aberg K A, van den Oord E J. Could monitoring methyl- ation markers aid the management of schizophrenia? [J]. Siomark Med,2014,8(5) :607 -611.
9Riordan H J, Antonini P, Murphy M F, Atypical anlipsy ehotics and metnbol- ic syndrome in patients with schizophrenia:risk factors,monitoring and healthcare implications[J].Am Health Drug Benefits,2011,4(5):292-302.
